Nurix Therapeutics (NRIX) EBT Margin (2019 - 2026)
Nurix Therapeutics (NRIX) reported EBT Margin of 1394.34% for Q1 2026, down 108896.0% year-over-year from N/an in Q1 2025, and down 142.02% quarter-over-quarter from 576.13% in Q4 2025.
Nurix Therapeutics (NRIX) EBT Margin (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has 8 years of EBT Margin data on file, last reported at 1394.34% in Q1 2026.
- EBT Margin for Q1 2026 came in at 1394.34%, down 108896.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 689.37% (down 32029.0% YoY), and the FY2025 annual result was 314.0%, up 4036.0% from the prior year.
- EBT Margin declined to 1394.34% in Q1 2026 per NRIX's latest filing, from 576.13% in the prior quarter.
- Over five years, EBT Margin peaked at 79.14% in Q2 2023 and troughed at 1394.34% in Q1 2026.
- A 5-year average of 466.5% and a median of 388.26% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2023 and 2026: EBT Margin surged 41196 bps in 2023, then sank 108896 bps in 2026.
- A 5-year view of EBT Margin shows it stood at 688.74% in 2022, then jumped by 60 bps to 276.77% in 2023, then tumbled by 59 bps to 440.69% in 2024, then slumped by 31 bps to 576.13% in 2025, then slumped by 142 bps to 1394.34% in 2026.
- Business Quant data shows NRIX's EBT Margin at 1394.34% in Q1 2026, 576.13% in Q4 2025, and 1094.77% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Nurix Therapeutics | 1.93 Bn | 1.39 Bn | - | -1,394.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -1,394.34% |
| Nov 30, 2025 | -576.13% |
| Aug 31, 2025 | -1,094.77% |
| May 31, 2025 | -284.69% |
| Feb 28, 2025 | -305.38% |
| Nov 30, 2024 | -440.69% |
| Aug 31, 2024 | -388.26% |
| May 31, 2024 | -367.65% |
| Feb 29, 2024 | -249.79% |
| Nov 30, 2023 | -276.77% |
| Aug 31, 2023 | -200.26% |
| May 31, 2023 | -79.14% |
| Feb 28, 2023 | -321.11% |
| Nov 30, 2022 | -688.74% |
| Aug 31, 2022 | -423.58% |
| May 31, 2022 | -397.14% |
| Feb 28, 2022 | -442.09% |
| Nov 30, 2021 | -509.17% |
| Aug 31, 2021 | -282.46% |
| May 31, 2021 | -370.09% |